Aliases & Classifications for Blepharitis

MalaCards integrated aliases for Blepharitis:

Name: Blepharitis 12 74 36 54 6 44 15 17 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:9423
KEGG 36 H01644
ICD9CM 34 373.0 373.4
MeSH 44 D001762
NCIt 50 C112183
SNOMED-CT 67 193907001 193920003
ICD10 32 H01.0
UMLS 71 C0005741 C0155181

Summaries for Blepharitis

KEGG : 36 Blepharitis is a chronic inflammatory condition of the eyelids associated with itchiness, redness, flaking, and crusting. It is among the most common ocular conditions affecting both children and adults. The etiology is complex and not fully understood, but the general consensus is that bacteria and inflammation contribute to the pathology. Blepharitis can be classified into anterior blepharitis and posterior blepharitis. Anterior blepharitis describes inflammation of the eyelid skin and eyelash follicles and may be accompanied by squamous debris or collarettes. Anterior blepharitis has classically been associated with Staphylococcus infection and seborrheic dermatitis. Posterior blepharitis describes inflammation of the meibomian glands and their orifices and may be a result of or cause of meibomian gland dysfunction (MGD). MGD is one cause of posterior blepharitis but others include infectious or allergic conjunctivitis, and rosacea. The diagnosis of blepharitis is almost always based on the history and clinical examination. Long-term management of symptoms may include daily eyelid cleansing routines and the use of therapeutic agents that reduce infection and inflammation. Recent clinical trials have shown that antibiotics and topical corticosteroids can produce significant improvement in signs and symptoms of blepharitis.

MalaCards based summary : Blepharitis is related to blepharoconjunctivitis and rosacea, and has symptoms including erythema of the eyelids An important gene associated with Blepharitis is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Fusidic Acid and Formaldehyde have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and bone marrow, and related phenotypes are digestive/alimentary and immune system

Disease Ontology : 12 An eyelid disease that is characterized by often chronic inflammation of the eyelid, generally the part where eyelashes grow.

Wikipedia : 74 Blepharitis is one of the most common ocular conditions characterized by inflammation, scaling,... more...

Related Diseases for Blepharitis

Diseases related to Blepharitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 blepharoconjunctivitis 32.0 IL4 CD4
2 rosacea 30.8 TNF MMP9 CCR6
3 conjunctivitis 30.7 TNF MUC16 MMP9 IL4
4 dermatophytosis 30.6 LTF CD4 CCR6
5 keratopathy 30.4 TNF LACRT IL4
6 folliculitis 30.2 IL4 CD4 CCR6
7 keratoconjunctivitis 30.1 TNF MUC5AC MUC16 MMP9 IL4
8 keratitis, hereditary 29.9 TNF MMP9 CD8A CD4 CCR6
9 vernal conjunctivitis 29.8 MUC5AC IL4 CCR6
10 pyoderma 29.8 TNF MMP9 CCR6
11 bacterial infectious disease 29.6 TNF LTF CD4 CCR6
12 allergic contact dermatitis 29.5 TNF IL4 CD4 CCR6
13 contact dermatitis 29.5 TNF IL4 CD4 CCR6
14 skin disease 29.4 TNF IL4 CD8A CD4 CCR6
15 dermatitis, atopic 29.4 TNF IL4 CD8A CD4 CCR6
16 eye disease 29.4 TNF MUC5AC LACRT IL4 CD8A CD4
17 keratoconjunctivitis sicca 29.3 TNF MUC5AC LTF LACRT IL4 CD4
18 crohn's disease 29.3 TNF LTF IL4 CD4 CCR6
19 colitis 29.3 TNF LTF IL4 CD4 CCR6
20 dermatitis 29.3 TNF STAT1 IL4 CD8A CD4 CCR6
21 eyelid disease 29.1 TNF MUC16 MMP9 LCN1 LACRT IL4
22 sarcoidosis 1 29.1 TNF STAT1 CD8A CD4 CCR6
23 dry eye syndrome 29.0 TNF PIP MUC5AC MUC4 LTF LCN1
24 disease by infectious agent 29.0 TNF IL4 CD8A CD4 CCR6
25 fungal infectious disease 28.8 TNF STAT1 IL4 CD8A CD4 CCR6
26 ulcerative blepharitis 11.2
27 squamous blepharitis 11.2
28 focal facial dermal dysplasia 3, setleis type 11.0
29 keratosis follicularis spinulosa decalvans, x-linked 11.0
30 ectodermal dysplasia 15, hypohidrotic/hair type 11.0
31 meibomian cyst 11.0
32 ichthyosis, congenital, autosomal recessive 11 10.9
33 hordeolum externum 10.9
34 geotrichosis 10.3 STAT1 CD4
35 chronic follicular conjunctivitis 10.3 LCN1 LACRT
36 autoimmune inner ear disease 10.3 TNF MMP9
37 ophthalmia nodosa 10.2 LTF LCN1
38 suppurative lymphadenitis 10.2 CD4 CCR6
39 anal canal adenocarcinoma 10.2 PIP MUC5AC
40 chromoblastomycosis 10.2 MMP9 IL4 CCR6
41 tropical endomyocardial fibrosis 10.2 TNF IL4
42 corneal ulcer 10.2 MUC5AC MMP9 LACRT
43 hyper ige recurrent infection syndrome 1 10.2 STAT1 CD4 CCR6
44 coccidioidomycosis 10.2 STAT1 CD4 CCR6
45 pouchitis 10.2 TNF LTF
46 telangiectasis 10.2
47 haemophilus influenzae 10.2 TNF LTF
48 rheumatoid arthritis interstitial lung disease 10.2 TNF CD4
49 mikulicz disease 10.2 IL4 CD4 CCR6
50 herpes simplex virus keratitis 10.2 CD4 CCR6

Comorbidity relations with Blepharitis via Phenotypic Disease Network (PDN):


Acute Cystitis Conjunctivitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Parkinson Disease, Late-Onset Schizophreniform Disorder

Graphical network of the top 20 diseases related to Blepharitis:



Diseases related to Blepharitis

Symptoms & Phenotypes for Blepharitis

UMLS symptoms related to Blepharitis:


erythema of the eyelids

MGI Mouse Phenotypes related to Blepharitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 CD4 IL4 MMP9 MUC5AC PIP PLA2G1B
2 immune system MP:0005387 9.4 CCR6 CD4 CD8A IL4 LTF MMP9

Drugs & Therapeutics for Blepharitis

Drugs for Blepharitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
2
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
3
Chloramphenicol Approved, Vet_approved Phase 4 56-75-7 298 5959
4
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
5
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
6
Besifloxacin Approved Phase 4 141388-76-3
7
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
8
Azithromycin Approved Phase 4 83905-01-5 55185 447043
9
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
10
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
11
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
12
Chamomile Experimental, Investigational Phase 4
13 Butylated Hydroxytoluene Phase 4
14 Erythromycin Estolate Phase 4
15 Erythromycin stearate Phase 4
16 Erythromycin Ethylsuccinate Phase 4
17 Anti-Infective Agents Phase 4
18 Anti-Bacterial Agents Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Anti-Allergic Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Tea Phase 4
23 Tea Tree Phase 4
24 Antiprotozoal Agents Phase 4
25 Antimalarials Phase 4
26 Protective Agents Phase 4
27 Viscosupplements Phase 4
28 Immunologic Factors Phase 4
29 Adjuvants, Immunologic Phase 4
30
Tea tree oil Experimental, Nutraceutical Phase 4 68647-73-4
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
32
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
33
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
34
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
35
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
36
Polyestradiol phosphate Approved Phase 3 28014-46-2
37
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
38
Tobramycin Approved, Investigational Phase 3 32986-56-4 5496 36294
39
Metronidazole Approved Phase 3 443-48-1 4173
40
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
41
Dipivefrin Approved Phase 3 52365-63-6 3105
42 Gastrointestinal Agents Phase 3
43 Estradiol 3-benzoate Phase 3
44 Contraceptives, Oral Phase 3
45 Anti-Inflammatory Agents Phase 3
46 Contraceptive Agents Phase 3
47 Hormones Phase 3
48 Hormone Antagonists Phase 3
49 BB 1101 Phase 3
50 Antineoplastic Agents, Hormonal Phase 3

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective-Randomized Trial. Unknown status NCT03105505 Phase 4 Permethrin 5%;Synthomycine 5%;Fusidic Acid 1% M/R Eye Drops
2 A Comparative Study in the Clinical and Microbial Efficacy of Topical Besifloxocin Ophthalmic Suspension 0.6% With Erythromycin Ophthalmic Ointment 0.5% BID for the Management of Acute Blepharitis Completed NCT01478256 Phase 4 Erythromycin;Besifloxocin
3 Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis - a Multi-centre, Randomised, Double-masked, Parallel-group, Phase IV Comparison Completed NCT01357538 Phase 4 Posiformin 2 %, bibrocathol;Placebo Comparator
4 Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis Completed NCT01456780 Phase 4 Loteprednol/tobramycin;Loteprednol;B+L Advanced Eye Relief Lubricant Drop
5 Swabs Containing Tea Tree Oil and Chamomile Oil Versus Baby Shampoo in Patients With Seborrheic Blepharitis: A Double-Blind Randomized Clinical Trial Completed NCT04678531 Phase 4 Swabs containing tea tree oil and chamomile oil;Baby shampoo
6 A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Four Weeks in Subjects With Posterior Blepharitis Completed NCT00656539 Phase 4 AzaSite®
7 A Multi-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone in Subjects With Blepharitis Completed NCT00629980 Phase 4 AzaSite®
8 A Multi-Center, Open-Label Study Evaluating the Cytokine and Eyelid Margin Bacterial Load Levels of Subjects Diagnosed With Chronic Blepharitis Following Dosing With AzaSite® (Azithromycin Ophthalmic Solution) 1% Completed NCT00629941 Phase 4 AzaSite®
9 A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Two Weeks in Subjects With Posterior Blepharitis Completed NCT00629590 Phase 4 AzaSite®
10 Randomized Double-Blind Trial of Lid Wipes Containing Terpinen-4-ol and Sodium Hyaluronate Versus Baby Shampoo in Patients With Seborrheic Blepharitis Completed NCT04441528 Phase 4 Lid wipes containing terpinen-4-ol and sodium hyaluronate;Baby shampoo
11 Lipids of the Human Tear Film and Their Effect on Tear Stability Completed NCT00803452 Phase 4 doxycycline;azithromycin
12 A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis Completed NCT01102244 Phase 3 Tobradex ST;Azasite
13 A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 Compared to AzaSite Alone, Dexamethasone Alone, and Vehicle in the Treatment of Subjects With Non-Bacterial Blepharitis Completed NCT01408082 Phase 3 ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined);Azasite;Dexamethasone
14 An Evaluation of the Safety and Efficacy of the Administration of a Fixed Combination of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops Compared With the Individual Administration of Moxifloxacin 0.5% and Dexamethasone 0.1% in the Treatment of Bacterial Ocular Inflammation and Infection (Blepharitis and/or Keratitis and/or Conjunctivitis) Completed NCT00732446 Phase 3 Moxifloxacin and Dexamethasone combined;Moxifloxacin;Dexamethasone
15 A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis Completed NCT01543490 Phase 3 ISV-305
16 Diagnosis of Demodex Blapharitis and Treatment With Ivermectin Gel 0.1%/ Metronidazole 1% Completed NCT02236403 Phase 3 Ivermectin 0.1% Metronidazole 1%
17 A Clinical Safety and Efficacy Evaluation of Zylet® Versus Tobradex in the Treatment of Blepharokeratoconjunctivitis Completed NCT01028027 Phase 3 Loteprednol and tobramycin;Tobramycin and dexamethasone
18 Randomised Controlled Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Completed NCT00796926 Phase 3 Systane Ultra eyedrops;Refresh eye drops
19 Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis Recruiting NCT04475432 Phase 2, Phase 3 TP-03;TP-03 Vehicle
20 Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
21 Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis (Pilot Phase II Clinical Study, Multicentre, Randomised, Double Masked, Comparative, 2 X 40 Patients) Completed NCT01089608 Phase 2 Azithromycin;Povidone
22 Tea Tree Oil in the Treatment of Chronic Blepharitis Completed NCT01073150 Phase 2 Tea Tree Oil
23 Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients With Facial Rosacea Completed NCT00560703 Phase 2 COL-101 (doxycycline, USP) capsules;placebo
24 Study of the Effect of Oral Azithromycin on Posterior Blepharitis Completed NCT01783860 Phase 2 Azithromycin;Doxycycline
25 Safety and Efficacy of Topical Interleukin-1-Receptor Antagonist in the Treatment of Signs and Symptoms of Posterior Blepharitis Completed NCT00681109 Phase 1, Phase 2 2.5% IL-1Ra;Placebo;5% IL-1Ra
26 The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) Completed NCT00894530 Phase 2 Azithromycin ophthalmic solution, 1%;Placebo
27 The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period Completed NCT00892970 Phase 2 Azithromycin ophthalmic solution, 1%;Placebo
28 A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerbations of Blepharitis Completed NCT03926026 Phase 2 Fluticasone Propionate;Placebo
29 A Phase I/II, Randomized, Double-Masked, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of AXR-270 Topical Eyelid Cream in Treating Posterior Blepharitis Associated With Meibomian Gland Dysfunction Completed NCT04469998 Phase 2 AXR-270 Low Dose;AXR-270 High Dose;AXR-270 Vehicle
30 A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease Completed NCT02218489 Phase 2 KPI-121;Vehicle
31 Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension, 0.1% QD for the Treatment of Acute Exacerbations of Blepharitis (Mississippi) Recruiting NCT04675242 Phase 2 NCX 4251;Placebo
32 An Evaluation of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates Terminated NCT00579020 Phase 2 Moxifloxacin/dexamethasone phosphate ophthalmic solution;Moxifloxacin ophthalmic solution 0.5%;Dexamethasone phosphate solution, 0.1%
33 A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis Terminated NCT01269658 Phase 2 Azithromycin ophthalmic solution, 1%;Vehicle
34 Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial Completed NCT01647217 Phase 1 Terpinen-4-ol
35 Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis: A Randomized, Outcomes-Assessor Masked, Clinical Trial Unknown status NCT03422146
36 A Multicenter Randomized, Double-Masked Study Comparing the Efficacy of Novabay iLid Cleanser Versus Vehicle on Ocular Skin Flora Unknown status NCT02455895
37 Blephacura Versus Baby Shampoo to Treat Blepharitis Completed NCT01115192
38 Randomized, Controlled Study With a Closed Sequential Design to Compare the Efficacy, Safety and Patient Satisfaction of Blephapad Combo vs. Standard Treatment for Eyelid Cleansing in Patients Affected by Bilateral Posterior Blepharitis. Completed NCT03301844
39 Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis Completed NCT02952079
40 Pilot Study for Treatment of Meibomian Gland Dysfunction (MGD) Prior to Cataract Surgery Completed NCT01808560
41 Evaluation and Treatment of Corneal and External Diseases and Anterior Segment Disorders Completed NCT00008541
42 Evaluation of SUMMIT BRUSH in Treatment of Blepharitis Recruiting NCT04603222
43 Effect of Probiotics on the Occurrence of Blepharitis in Adults and Children Recruiting NCT04742855
44 Clinical Correlation Between Facial Demodicosis and Ocular Demodicosis Recruiting NCT04377841
45 Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa : Study of a Handheld in Vivo Confocal Microscope and of a Fluorescent in Vivo Confocal Microscope Recruiting NCT02386774
46 Dry Eye Outcome and Prescription Study Recruiting NCT03652415
47 Topical Cadaveric-Derived Corneal Epithelial Stem Cell Transplant Therapy for the Treatment of Severe Dry Eye Disease Enrolling by invitation NCT03302273
48 The Efficacy of Microblephararoexfoliation in the Treatment of Anterior Blepharitis Terminated NCT04290455
49 Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis Terminated NCT01560962 povidone iodine;Povidone-Iodine;Azithromycin;tobramycin-dexmethasone
50 Ocular Comfort and Markers of Inflammation in Subjects Undergoing Lid Hygiene Therapy Terminated NCT02938078

Search NIH Clinical Center for Blepharitis

Cochrane evidence based reviews: blepharitis

Genetic Tests for Blepharitis

Anatomical Context for Blepharitis

MalaCards organs/tissues related to Blepharitis:

40
Eye, Skin, Bone Marrow, Brain, T Cells, Neutrophil, Breast

Publications for Blepharitis

Articles related to Blepharitis:

(show top 50) (show all 1304)
# Title Authors PMID Year
1
Influence of topical anesthesia on tests diagnostic of blepharitis-associated dry eye syndrome. 54 61
9145691 1997
2
Effect of 808-nm Laser Photobiomodulation Treatment in Blepharitis Rat Model. 61
33165014 2021
3
Predisposing factors, microbiological features and outcomes of patients with clinical presumed concomitant microbial and herpes simplex keratitis. 61
33608639 2021
4
Herpes simplex virus-1 KOS-63 strain is virulent and causes titer-dependent corneal nerve damage and keratitis. 61
33608598 2021
5
Clinical Profile of Melkersson-Rosenthal Syndrome/Orofacial Granulomatosis: A Review of 51 Patients. 61
33573395 2021
6
The Effect of Therapeutic Meibomian Glands Expression on Evaporative Dry Eye: A Prospective Randomized Controlled Trial. 61
32602744 2021
7
Investigation of the Demodex Lid Infestation with in Vivo Confocal Microscopy versus Light Microscopy in Patients with Seborrheic Blepharitis. 61
33560183 2021
8
Critical value of Demodex count per lash for symptomatic and clinical improvement of Demodex blepharitis. 61
33608643 2021
9
DOCK2 contributes to endotoxemia-induced acute lung injury in mice by activating proinflammatory macrophages. 61
33382969 2021
10
Dry anophthalmic socket syndrome - morphological alterations in meibomian glands. 61
33564141 2021
11
Eyelash loss in frontal fibrosing alopecia: Microscopic features of two cases. 61
33160730 2021
12
Efficacy of Azithromycin Eyedrops for Individuals With Meibomian Gland Dysfunction-Associated Posterior Blepharitis. 61
32649390 2021
13
Aggregated neutrophil extracellular traps occlude Meibomian glands during ocular surface inflammation. 61
33401018 2021
14
The Effect of Volatile Oil from Chinese Mugwort Leaf on Human Demodecid Mites In Vitro. 61
33394383 2021
15
[Chronic blepharitis with conjunctival granulomas: A case of systemic sarcoidosis]. 61
33509652 2021
16
Topical Steroids and Antibiotics for Adult Blepharokeratoconjunctivitis (BKC): A Meta-Analysis of Randomized Clinical Trials. 61
33520297 2021
17
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. 61
33481203 2021
18
Capnocytophaga canimorsus blebitis: case report and review of literature. 61
33499831 2021
19
Randomized trial of topical periocular castor oil treatment for blepharitis. 61
32422285 2021
20
Anterior segment optical coherence tomography features of pseudoepitheliomatous hyperplasia of the ocular surface: a study of 9 lesions. 61
32839863 2021
21
Ocular Findings in Pontine Tegmental Cap Dysplasia. 61
32398424 2020
22
Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments. 61
33349225 2020
23
Targeted steroid ointment application to the lid margins in ocular graft-versus-host disease associated blepharitis treatment. 61
33359869 2020
24
Moraxella keratitis: epidemiology and outcomes. 61
32648113 2020
25
Safety and Efficacy of an Augmented Intense Pulse Light Protocol for Dry Eye Syndrome and Blepharitis. 61
33370543 2020
26
Unilateral facial erythematous patch as the presenting sign of systemic lupus erythematosus. 61
32924830 2020
27
Knockout of Cyp26a1 and Cyp26b1 during postnatal life causes reduced lifespan, dermatitis, splenomegaly, and systemic inflammation in mice. 61
33105029 2020
28
The Ocular Manifestations of COVID-19 Through Conjunctivitis. 61
33489624 2020
29
[Demodex and ocular surface disease]. 61
33127178 2020
30
Effects of Terpinen-4-ol on Meibomian Gland Epithelial Cells In Vitro. 61
32947397 2020
31
Symptomatic vulvar demodicosis: A case report and review of the literature. 61
33448447 2020
32
Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. 61
33148049 2020
33
Association between Demodex folliculorum and Metabolic Syndrome. 61
33017081 2020
34
Malassezia species may play potential roles in the pathogenesis of meibomian gland dysfunction. 61
33254481 2020
35
Monocanalicular silicone stent implantation in children with congenital nasolacrimal duct obstruction 61
33249409 2020
36
Impact of COVID-19 pandemic and lockdown on eye emergencies. 61
33213198 2020
37
Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Longitudinal Perspective and Proposed Management Criteria. 61
32574770 2020
38
Ocular surface manifestation of COVID-19 and tear film analysis. 61
33214658 2020
39
Prospective evaluation of a new intense pulsed light, thermaeye plus, in the treatment of dry eye disease due to meibomian gland dysfunction. 61
33121905 2020
40
Anterior segment optical coherence tomography, in vivo confocal microscopy, histopathologic, and immunohistochemical findings in a patient with multiple endocrine neoplasia type 2b. 61
32718216 2020
41
Ocular Surface Disorders in Patients with Human Immunodeficiency Virus (HIV) Infection. 61
32501744 2020
42
Massive Demodicosis of the Eyes in a Patient with Sjögren Syndrome: A Case Report. 61
33128728 2020
43
Therapeutic potential of castor oil in managing blepharitis, meibomian gland dysfunction and dry eye. 61
33037703 2020
44
Is there enough evidence for the routine recommendation of eyelid wipes? A systematic review of the role of eyelid wipes in the management of blepharitis. 61
32835674 2020
45
Comparison of Biomicroscopy and Light Microscopy Findings in Demodex Diagnosis in Patients With Chronic Blepharitis. 61
31658176 2020
46
Prevalence and antibiotic susceptibility of bacteria isolated in patients affected with blepharitis in a tertiary eye centre in Spain. 61
31232091 2020
47
Prevalence of Ocular Demodicosis and Ocular Surface Conditions in Patients Selected for Cataract Surgery. 61
32977656 2020
48
Corneal sterile infiltration induced by topical use of ocular hypotensive agent. 61
31096781 2020
49
Acute inflammatory Demodex-induced pustulosis in an immunocompetent patient related to topical steroid use. 61
32729151 2020
50
CHARGE syndrome without colobomas: Ophthalmic findings. 61
32914532 2020

Variations for Blepharitis

ClinVar genetic disease variations for Blepharitis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1):c.821G>A (p.Arg274Gln) SNV Pathogenic 30085 rs387906760 2:191859910-191859910 2:190995184-190995184

Expression for Blepharitis

Search GEO for disease gene expression data for Blepharitis.

Pathways for Blepharitis

Pathways related to Blepharitis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 TNF STAT1 PLA2G6 MUC5AC MUC4 MUC16
2
Show member pathways
13.09 TNF PLA2G6 PLA2G1B PIP IL4 CD4
3
Show member pathways
12.71 TNF STAT1 IL4 CD8A CD4
4
Show member pathways
12.4 TNF STAT1 IL4 CD8A CD4
5
Show member pathways
12.16 TNF MUC5AC MMP9 IL4
6 11.78 TNF PLA2G6 MMP9 IL4
7 11.73 TNF IL4 CD8A CD4
8
Show member pathways
11.71 STAT1 IL4 CD4
9 11.68 TNF STAT1 MMP9 IL4
10
Show member pathways
11.61 TNF STAT1 CD4
11
Show member pathways
11.61 STAT1 IL4 CD8A CD4
12 11.6 STAT1 MMP9 CD4
13 11.58 TNF CD8A CD4
14 11.51 TNF IL4 CCR6
15 11.47 TNF MMP9 IL4
16 11.25 TNF IL4 CD8A CD4
17 10.92 TNF IL4 CD8A CD4 CCR6
18 10.79 TNF IL4 CD4

GO Terms for Blepharitis

Cellular components related to Blepharitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF PLA2G1B PIP MUC5AC MUC4 MUC16
2 extracellular space GO:0005615 9.44 TNF PLA2G6 PLA2G1B PIP MUC5AC MUC4

Biological processes related to Blepharitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 TNF IL4 CD8A CD4 CCR6
2 positive regulation of protein phosphorylation GO:0001934 9.76 TNF PLA2G6 MMP9 CD4
3 O-glycan processing GO:0016266 9.61 MUC5AC MUC4 MUC16
4 humoral immune response GO:0006959 9.58 TNF LTF CCR6
5 cytokine-mediated signaling pathway GO:0019221 9.55 TNF STAT1 MMP9 IL4 CD4
6 positive regulation of ceramide biosynthetic process GO:2000304 9.51 TNF PLA2G6
7 antibacterial humoral response GO:0019731 9.5 PLA2G6 PLA2G1B LTF
8 negative regulation of lipopolysaccharide-mediated signaling pathway GO:0031665 9.49 LTF LACRT
9 T cell activation GO:0042110 9.43 IL4 CD8A CD4
10 positive regulation of mononuclear cell migration GO:0071677 9.37 TNF IL4
11 innate immune response in mucosa GO:0002227 9.13 PLA2G1B LTF IL4
12 retina homeostasis GO:0001895 8.92 PIP LTF LCN1 CST4

Molecular functions related to Blepharitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TNF STIM2 STAT1 PLA2G6 PLA2G1B PIP
2 cysteine-type endopeptidase inhibitor activity GO:0004869 8.92 LTF LCN1 CST6 CST4

Sources for Blepharitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....